Background
Sermorelin and related growth hormone-releasing hormone (GHRH) analogs stimulate pulsatile GH secretion from the pituitary, maintaining the physiological pattern of GH release (unlike exogenous HGH which floods continuously). CJC-1295 is a modified GHRH analog with extended half-life due to albumin binding.
This study established the pharmacokinetics and IGF-1 response profile for GHRH analogs, forming the basis for current clinical use of sermorelin and CJC-1295/Ipamorelin combinations.
Methods
Two-part dose-escalation study. Part 1: single doses (30, 60, 90, 120, 180 μg/kg) in healthy adults. Part 2: two weekly doses over 28 days. GH pulses, IGF-1, IGFBP-3, and safety parameters measured.
Key Findings
| Parameter | Result |
|---|---|
| GH peak after injection | 10–15× baseline at 2 hours |
| Duration of GH elevation | 6 days post single dose |
| IGF-1 increase | 1.5–3.0× baseline (dose-dependent) |
| IGFBP-3 increase | Parallel to IGF-1 |
| Adverse events | Transient flushing, injection site reactions |
| Antibody formation | None detected |
Clinical Significance
This trial provided foundational evidence that GHRH analogs can produce sustained, physiologically patterned GH axis stimulation — crucial differentiation from supraphysiologic exogenous HGH. The pulsatile pattern preserves pituitary feedback and reduces risks associated with constant GH elevation.
These findings support the rationale for using sermorelin and CJC-1295 in anti-aging protocols targeting IGF-1 optimization, body composition improvement, and recovery enhancement.
Limitations
- Small sample (65 participants)
- Short duration — no long-term body composition or outcome data
- Primarily pharmacokinetic; not powered for clinical endpoints
- Healthy adults only; effects in GH-deficient populations may differ